These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38112549)

  • 1. Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis.
    Goins SM; Jiang H; van der Pol CB; Salameh JP; Lam E; Adamo RG; McInnes MDF; Costa AF; Tang A; Alhasan AS; Allen BC; Reiner CS; Clarke C; Cerny M; Wang J; Choi SH; Fraum TJ; Ludwig DR; Song B; Joo I; Kang Z; Kierans AS; Kim SY; Kwon H; Ronot M; Podgórska J; Rosiak G; Song JS; Bashir MR
    Radiology; 2023 Dec; 309(3):e231656. PubMed ID: 38112549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.
    Jiang H; Song B; Qin Y; Wei Y; Konanur M; Wu Y; Zaki IH; McInnes MDF; Lafata KJ; Bashir MR
    J Magn Reson Imaging; 2022 Feb; 55(2):493-506. PubMed ID: 34236120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Performance of 2018 LI-RADS versus Modified LIRADS (mLI-RADS): An Individual Participant Data Meta-Analysis.
    Goins SM; Jiang H; van der Pol CB; Salameh JP; Lam E; Adamo RG; McInnes MDF; Costa AF; Clarke C; Choi SH; Fraum TJ; Ludwig DR; Song B; Joo I; Kierans AS; Kim SY; Kwon H; Podgórska J; Rosiak G; Bashir MR
    J Magn Reson Imaging; 2024 Sep; 60(3):1082-1091. PubMed ID: 38038346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
    Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
    AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
    [No Abstract]   [Full Text] [Related]  

  • 5. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
    Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

  • 8. Liver Imaging Reporting and Data System version 2018 category 5 for diagnosing hepatocellular carcinoma: an updated meta-analysis.
    Lee S; Kim YY; Shin J; Roh YH; Choi JY; Chernyak V; Sirlin CB
    Eur Radiol; 2024 Mar; 34(3):1502-1514. PubMed ID: 37656177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.
    Choi SJ; Choi SH; Kim DW; Kwag M; Byun JH; Won HJ; Shin YM
    J Hepatol; 2023 Mar; 78(3):596-603. PubMed ID: 36402451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Performance of LI-RADS v2018 versus KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging with Hepatobiliary Agent: A Systematic Review and Meta-Analysis of Comparative Studies.
    Shin J; Lee S; Yoon JK; Son WJ; Roh YH; Chung YE; Choi JY; Park MS
    Gut Liver; 2023 May; 17(3):466-474. PubMed ID: 36317516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.
    Chen J; Kuang S; Zhang Y; Tang W; Xie S; Zhang L; Rong D; He B; Deng Y; Xiao Y; Shi W; Fowler K; Wang J; Sirlin CB
    Abdom Radiol (NY); 2021 Apr; 46(4):1530-1542. PubMed ID: 33040166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?
    Ghadimi M; Birnbaum J; Kamel IR; Sirlin CB; Chernyak V
    Eur Radiol; 2022 May; 32(5):3327-3333. PubMed ID: 34807269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Performance of CT/MRI Liver Imaging Reporting and Data System v2017 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Lee S; Kim SS; Roh YH; Choi JY; Park MS; Kim MJ
    Liver Int; 2020 Jun; 40(6):1488-1497. PubMed ID: 32145134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
    De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
    Lee S; Kim YY; Shin J; Hwang SH; Roh YH; Chung YE; Choi JY
    J Am Coll Radiol; 2020 Oct; 17(10):1199-1206. PubMed ID: 32640250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
    Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
    Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis.
    van der Pol CB; McInnes MDF; Salameh JP; Levis B; Chernyak V; Sirlin CB; Bashir MR; Allen BC; Burke LMB; Choi JY; Choi SH; Forner A; Fraum TJ; Giamperoli A; Jiang H; Joo I; Kang Z; Kierans AS; Kang HJ; Khatri G; Kim JH; Kim MJ; Kim SY; Kim YY; Kwon H; Lee JM; Lewis SC; McGinty KA; Mulazzani L; Park MS; Piscaglia F; Podgórska J; Reiner CS; Ronot M; Rosiak G; Song B; Song JS; Tang A; Terzi E; Wang J; Wang W; Wilson SR; Yokoo T
    Radiology; 2022 Feb; 302(2):326-335. PubMed ID: 34783596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim SS; Chang DR; Kim H; Kim MJ
    Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.